News | March 07, 2024
Briefs: Zydus, Advanced Enzyme Technologies, Link Pharma Chem and ANVISA
ANVISA issues CGMP to Concord Biotech’s Unit I
ANVISA issues CGMP to Concord Biotech’s Unit I
Acquisition of exclusive commercialization rights for European markets
Collaborative Research in AYUSH is extremely important as it bridges the gap between traditional knowledge and modern scientific research
Launch of Indian public health standards for Ayush healthcare facilities
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Subscribe To Our Newsletter & Stay Updated
